Labiotech.eu

News and Trends 6 Nov 2017

Get your Company Ready for the EU’s New Data Protection Law

With the beginning of summer next year, not only temperatures will rise, but possibly also temperaments, as the European Union’s new data protection law takes effect. The highly tightened measures to protect personal data will mean that companies worldwide have a lot of adjusting to do. Like most new regulations, the General Data Protection Regulation […]

November 6, 2017 - 9 minutesmins - By External Contributor

News and Trends 6 Nov 2017

Swiss Biotech Pulls Major Investors into €42M Series B for Cancer Vaccines

NousCom is developing semi-personalized medicine that convinced investors like Abingworth to go in big for its off-the-shelf neoantigen vaccines. Based in Basel and run by a team of serial entrepreneurs with over 15 years of experience, NousCom is finding the middle ground between broadly applicable treatments and personalized medicine. “We are the only company working […]

November 6, 2017 - 3 minutesmins - By Evelyn Warner

CureVac Moderna Therapeutics Biotech Unicorn Battle mRNA

Interview 6 Nov 2017

Battle of the Biotech Unicorns: CureVac vs. Moderna

An interview never seen before. We brought together the founders and CEOs of the two biotech unicorns pioneering mRNA therapy: CureVac in Germany and Moderna Therapeutics in the US. The idea of messenger RNA as a therapy is simple but brilliant: instead of giving a protein to a patient, you give their body the instructions […]

November 6, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Nov 2017

Bioart from the Ocean Depths: Underwater Sounds

What can art tell us about the mysteries of underwater life? Robertina Šebjanič explores the fascinating world of jellyfish, shrimps, fish and sea urchins. Robertina Šebjanič is an artist and researcher fascinated by underwater life. Her work explores the relationship between humans and animals, often through an unusual medium: sound. Šebjanič collaborates with other artists, […]

November 4, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Nov 2017

Swiss Biotech Gets €12M as its Alzheimer’s Candidate Enters Phase II

AC Immune’s Anti-Tau antibody for the treatment of Alzheimer’s disease has reached Phase II, prompting milestone payments from Genentech. Today, the first patient in a Phase II trial was dosed with AC Immune’s anti-Tau antibody for the treatment of Alzheimer’s disease. This triggered a milestone payment of CHF 14M (€12M) from its collaborator, Genentech, as part of an agreement […]

November 2, 2017 - 2 minutesmins - By Alex Dale

News and Trends 2 Nov 2017

Swedish Biotech Team Steps Up in the Fight Against Type 2 Diabetes

Two Swedish biotechs, Betagenon and Baltic Bio, have announced promising preliminary Phase IIa results for their Type 2 Diabetes candidate. Betagenon develops therapies for chronic energy balance disorders and has received funding from the EU’s program for research and innovation, Horizon 2020. Privately funded Betagenon has partnered up with Baltic Bio to share the profits from a type […]

November 2, 2017 - 2 minutesmins - By Alex Dale

News and Trends 2 Nov 2017

Close to Launching Gene Therapy, Dutch Biotech Raises Over $91M on the Nasdaq

Update (2/11/2017): uniQure has closed its public offering raising over $91m (€78M) on the Nasdaq, taking advantage of a massive stock jump triggered by the announcement that an improved version of its gene therapy for hemophilia B will enter Phase III trials. Originally published on 24/10/2017 UniQure launched a public offering, perfectly timed with a rise in […]

November 2, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Nov 2017

German Biotech Pockets €18M in its Series A to Propel Autoimmune Disease Candidate Forward

Topas Therapeutics received an extra €4M from Boehringer Ingelheim Venture Fund to help its autoimmune disease candidates accelerated through trials. Hamburg-based Topas Therapeutics, a spin-off from Evotec, develops products for autoimmune diseases with high medical need. With the announcement of a €18M Series A, it hopes to take begin moving its candidates into the clinic. It had raised €14M thanks to investment from Epidarex […]

November 2, 2017 - 2 minutesmins - By Alex Dale

News and Trends 2 Nov 2017

AstraZeneca and Moderna want to beat Novartis at Treating Heart Failure

AstraZeneca will work with Moderna Therapeutics to bring together to the market an mRNA version of Novartis’ failed heart failure drug Serelaxin. AstraZeneca has signed a deal with US biotech Moderna Therapeutics to co-develop and co-commercialize an mRNA drug encoding for the protein hormone relaxin. The therapy has the same target as Novartis’ Serelaxin (RLX030), a drug that was dropped in March […]

November 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Labiotech MATERIALS BerlinPartner Infographic ArticleHeader FINAL

News and Trends 2 Nov 2017

Infographic: The Berlin Biotech Ecosystem

Together with Berlin Partner for Business and Technology, we have created an absolutely amazing infographic full of cool & fun facts about the Berlin Biotech Ecosystem. Click on the image below to view the complete infographic! Do you want to learn more about Berlin and its Biotech ecosystem? Visit Berlin Partner for […]

November 2, 2017 - 1 minutemin - By External Contributor

Interview 2 Nov 2017

Meet the Top Biotech Investor Who Picked His Career By Accident

Kevin Johnson, Partner at Medicxi, joined us last week for our Meetup in London. He told us how he ended as an investor despite starting in biotech. Fresh from his PhD at Cambridge, Johnson stepped into biotech and led the development of a number of human antibodies at Cambridge Antibody Technology (CAT). The company was eventually responsible for […]

November 2, 2017 - 4 minutesmins - By Alex Dale

More News! 1 Nov 2017

Swiss Biotech & French Pharma Reverse Damage in Multiple Sclerosis

A candidate multiple sclerosis treatment from GeNeuro and its partner Servier showed some remyelination in a post hoc analysis of Phase IIb data. GeNeuro’s stock rose by 30% on Monday following an announcement of promising results from its relapsing-remitting multiple sclerosis drug, GNbAC1. After six months, the highest dose demonstrated an anti-inflammatory effect and seemed to stimulate […]

November 1, 2017 - 2 minutesmins - By Evelyn Warner

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Get your Company Ready for the EU’s New Data Protection Law

Swiss Biotech Pulls Major Investors into €42M Series B for Cancer Vaccines

Battle of the Biotech Unicorns: CureVac vs. Moderna

Bioart from the Ocean Depths: Underwater Sounds

Swiss Biotech Gets €12M as its Alzheimer’s Candidate Enters Phase II

Swedish Biotech Team Steps Up in the Fight Against Type 2 Diabetes

Close to Launching Gene Therapy, Dutch Biotech Raises Over $91M on the Nasdaq

German Biotech Pockets €18M in its Series A to Propel Autoimmune Disease Candidate Forward

AstraZeneca and Moderna want to beat Novartis at Treating Heart Failure

Infographic: The Berlin Biotech Ecosystem

Meet the Top Biotech Investor Who Picked His Career By Accident

Swiss Biotech & French Pharma Reverse Damage in Multiple Sclerosis

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!